Register for our free email digests:
Karyopharm Therapeutics
http://www.karyopharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Karyopharm Therapeutics
EMA: Moment Of Truth For Two Curative Therapies & A Possible Cholesterol-Lowering Blockbuster
The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.
Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- NPM Pharma, Inc.